Repligen (RGEN) Stock Price, News & Analysis

Company Overview

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins. Repligen also produces single-use filtration devices and XCell ATF (alternating tangential flow) systems, which are used to improve cell culture performance and scalability. These products are integrated into manufacturing workflows by contract development and manufacturing organizations, academic research centers and global biopharmaceutical firms.

Over its history, Repligen has expanded through strategic acquisitions and internal product development to broaden its bioprocessing platform. Notable additions include the acquisitions of TangenX for flat-sheet filtration technology and the chromatography resin business from Novasep, enhancing its geographic footprint and product diversity. This growth strategy has enabled Repligen to offer end-to-end solutions from early-stage process development through commercial-scale production.

Repligen serves customers across North America, Europe and Asia, operating manufacturing and research facilities to support a global client base. Under the leadership of President and CEO Matthew Scullin, the company continues to invest in innovation, scaling its operations to meet the evolving demands of the biopharmaceutical industry while maintaining a focus on product quality and customer support.

Key Stats

• Today's Range: $118.52 to $124.01
• 50-Day Range: $102.87 to $132.70
• 52-Week Range: $100.99 to $175.77
• Volume: 695,090 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $6.83 billion
• P/E Ratio: 136.00
• Dividend Yield: N/A
• Price Target: $164.64
• Consensus Rating: Moderate Buy

Repligen Stock Analysis - MarketRank™

Repligen scored higher than 78% of companies evaluated by MarketBeat, and ranked 169th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Repligen has a consensus price target of $164.64, representing about 37.3% upside from its current price of $119.90.

Amount of Analyst Coverage

Repligen has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 22.61%

Earnings Growth

Earnings for Repligen are expected to grow by 22.61% in the coming year, from $1.99 to $2.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Repligen is 136.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Repligen is 136.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.14.

Price to Earnings Growth Ratio

Repligen has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Repligen has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.16% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 3.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Repligen has recently increased by 3.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Repligen does not currently pay a dividend.

Dividend Growth

Repligen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.60

News Sentiment

Repligen has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Repligen this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

2 people have added Repligen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Repligen insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.60% of the stock of Repligen is held by insiders.

Percentage Held by Institutions

97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 6/02/2026
• 46th Annual William Blair Growth Stock Conference: 6/03/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGEN
• CIK: 730272
• Web: www.repligen.com
• Phone: (781) 250-0111
• Fax: 781-250-0115
• Employees: 2,000
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Repligen: $164.64
• High Price Target: $208.00
• Low Price Target: $142.00
• Potential Upside/Downside: +35.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.90
• Trailing P/E Ratio: 136.00
• Forward P/E Ratio: 60.86
• P/E Growth: 2.39
• Net Income: $48.89 million
• Net Margins: 6.73%
• Pretax Margin: 7.36%
• Return on Equity: 4.88%
• Return on Assets: 3.48%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 9.20
• Quick Ratio: 7.78

Sales & Book Value

• Annual Sales: $738.26 million
• Price / Sales: 9.25
• Cash Flow: $3.34 per share
• Price / Cash Flow: 36.28
• Book Value: $37.42 per share
• Price / Book: 3.24

Miscellaneous

• Outstanding Shares: 56,410,000
• Free Float: 56,070,000
• Market Cap: $6.83 billion
• Optionable: Optionable
• Beta: 1.09